Boehringer Ingelheim × Owkin
Boehringer Ingelheim licensed Owkin's AI platform, K Pro, and associated multimodal patient data to accelerate discovery in oncology and immunology. The deal includes access to existing oncology datasets and the generation of new data for immunology research. [50, 51, 53, 55] The financial terms of the agreement were not disclosed. [51, 52, 62]
The asset
License for K Pro AI Scientist platform, existing multimodal oncology patient data, and generation of new multimodal patient data in immunology.
- 3k total patients in MOSAIC dataset
The record
- Seller status
- Going concern
- Sector
- AI drug discovery
- Modalities
- genomic, clinical, imaging, spatial transcriptomics, single-cell RNA sequencing, whole exome sequencing
- Personal data
- Owkin licenses, sources, and generates multimodal patient data in collaboration with its global patient data network; specific PII treatment details not disclosed in sources.
What it means if you hold data
This deal highlights a trend of pharmaceutical companies licensing both AI platforms and the underlying high-quality, multimodal patient data to fuel their R&D engines. It positions the data itself, and the AI to interpret it, as a critical asset for future drug discovery.
Sources
- unite.ai — https://www.unite.ai/boehringer-ingelheim-licenses-owkins-k-pro-ai-scientist-and-patient-data/
- contractpharma.com — https://www.contractpharma.com/contents/view_breaking-news/2026-09-02/boehringer-ingelheim-licenses-owkins-k-pro-ai-scientist-for-accelerated-discovery-in-oncology-immunology/
- thestar.com.my — https://www.thestar.com.my/tech/tech-news/2026/09/02/owkin-signs-ai-drug-discovery-deal-with-boehringer-for-cancer-immunology